Success Metrics

Clinical Success Rate
87.5%

Based on 28 completed trials

Completion Rate
88%(28/32)
Active Trials
3(8%)
Results Posted
36%(10 trials)
Terminated
4(10%)

Phase Distribution

Ph phase_2
3
8%
Ph phase_1
9
23%
Ph phase_4
13
33%
Ph not_applicable
5
13%
Ph phase_3
6
15%

Phase Distribution

9

Early Stage

3

Mid Stage

19

Late Stage

Phase Distribution36 total trials
Phase 1Safety & dosage
9(25.0%)
Phase 2Efficacy & side effects
3(8.3%)
Phase 3Large-scale testing
6(16.7%)
Phase 4Post-market surveillance
13(36.1%)
N/ANon-phased studies
5(13.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

28 of 32 finished

Non-Completion Rate

12.5%

4 ended early

Currently Active

3

trials recruiting

Total Trials

39

all time

Status Distribution
Active(4)
Completed(28)
Terminated(4)
Other(3)

Detailed Status

Completed28
Terminated4
unknown3
Active, not recruiting2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
39
Active
3
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (25.0%)
Phase 23 (8.3%)
Phase 36 (16.7%)
Phase 413 (36.1%)
N/A5 (13.9%)

Trials by Status

active_not_recruiting25%
completed2872%
terminated410%
unknown38%
recruiting13%
not_yet_recruiting13%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT05450978

Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding

Recruiting
NCT02219373Phase 3

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

Not Yet Recruiting
NCT07252453Not Applicable

Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia

Active Not Recruiting
NCT03196466

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed
NCT01679002Phase 1

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Completed
NCT06849219Phase 4

Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia

Active Not Recruiting
NCT00849797Phase 1

Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions

Completed
NCT00850174Phase 1

Oxcarbazepine 600 mg Tablets Under Fasting Conditions

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT00154323Phase 4

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

Completed
NCT05697614Phase 4

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

Unknown
NCT04996199Phase 4

Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial

Unknown
NCT00467753Not Applicable

Oxcarbazepine Versus Placebo in Childhood Autism

Completed
NCT03695094Phase 1

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Completed
NCT01051193Phase 2

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Completed
NCT02456896Phase 4

Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder

Completed
NCT02104661Phase 2

Protective Role of Oxcarbazepine in Multiple Sclerosis

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT00616681Not Applicable

Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions

Completed
NCT00618046Not Applicable

Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39